91ֱ��

All publications

Journal articles

• Latimer N (2024) A comparison of the effectiveness of different treatment regimens for pancreatic cancer using English cancer registry data. SCHARR HEDS Discussion Paper(24.05).
• Bullement A, Edmondson-Jones M, Guyot P, Welton NJ, Baio G, Stevenson M & Latimer NR (2024) . PharmacoEconomics.
• Taylor K, Latimer NR, Douglas T, Hatswell AJ, Ho S, Okorogheye G, Borril J, Chen C, Kim I & Bertwistle D (2024) . PharmacoEconomics.
• Bullement A, Edmondson-Jones M & Latimer N (2024) . BMC Cancer, 24(1), 879.
• Jennings AC, Rutherford MJ, Latimer NR, Sweeting MJ & Lambert PC (2023) . Value in Health, S1098-3015(23)06241.
• Bell Gorrod H, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) . Value in Health, 26(12), S394-S394.
• Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) . Value in Health, 26(12), S13-S13.
• Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) . Value in Health, 26(12), S423-S424.
• Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) . Value in Health, 26(12), S421-S422.
• Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) . Value in Health, 26(12), S365-S365.
• Broomfield J, Abrams K, Latimer N, Guglieri M, Rutherford M & Crowther M (2023) . Brain and Behavior, e3331.
• Turner AJ, Sammon C, Latimer N, Adamson B, Beal B, Subbiah V, Abrams KR & Ray J (2023) . PharmacoEconomics, 1-12.
• Lee S, Lambert PC, Sweeting MJ, Latimer NR & Rutherford MJ (2023) . Value in Health.
• Bullement A, Stevenson MD, Baio G, Shields GE & Latimer NR (2023) . Medical Decision Making, 43(5), 610-620.
• Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) TREATMENT EFFECT WANING IN IMMUNO-ONCOLOGY HEALTH TECHNOLOGY ASSESSMENTS: A REVIEW OF ASSUMPTIONS AND SUPPORTING EVIDENCE. VALUE IN HEALTH, 26(12), S365-S365.
• Bullement A, Critchlow S, Stevenson MD, Baio G & Latimer N (2022) A REVIEW OF EXTERNAL EVIDENCE USED TO SUPPORT SURVIVAL EXTRAPOLATION IN ASSESSMENTS OF CANCER DRUGS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). VALUE IN HEALTH, 25(12), S340-S340.
• Morga A, Latimer NR, Scott M, Hawkins N, Schlichting M & Wang J (2022) . Value in Health.
• Nimmo A, Latimer N, Oniscu GC, Ravanan R, Taylor DM & Fotheringham J (2022) . Transplant International, 35.
• Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) . Pilot and Feasibility Studies, 8(1), 74-74.
• Gomes M, Latimer N, Soares M, Dias S, Baio G, Freemantle N, Dawoud D, Wailoo A & Grieve R (2022) . PharmacoEconomics.
• Latimer NR & Adler AI (2022) . BMJ Medicine, 1.
• Adler AI & Latimer NR (2021) . JAMA : the Journal of the American Medical Association, 325(20), 2110-2111.
• Latimer NR, Towse A & Henshall C (2021) . Expert Review of Pharmacoeconomics & Outcomes Research.
• Srivastava T, Latimer NR & Tappenden P (2021) . PharmacoEconomics.
• Fotheringham J, Latimer N, Froissart M, Kronenberg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler DC (2020) . Clinical Kidney Journal.
• Woods BS, Sideris E, Palmer S, Latimer N & Soares M (2020) . Value in Health.
• Palmer R, Dimairo M, Latimer N, Cross E, Brady M, Enderby P, Bowen A, Julious S, Harrison M, Alshreef A , Bradley E et al (2020) . Health Technology Assessment, 24(19), 1-176.
• Latimer N, White IR, Tilling K & Siebert U (2020) . Statistical Methods in Medical Research.
• Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB & Karnon J (2020) . Value in Health.
• Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D & Sowdani A (2019) . Medical Decision Making.
• Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2019) . Advances in Therapy.
• Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) . Medical Decision Making.
• Adler AI, Ting S, Dent R & Latimer N (2019) . The Lancet Diabetes & Endocrinology, 7(10), 750-751.
• Palmer R, Dimairo M, Cooper C, Enderby P, Brady M, Bowen A, Latimer N, Julious S, Cross E, Alshreef A , Harrison M et al (2019) . The Lancet Neurology, 18(9), 821-833.
• Thomas SA, Drummond AER, Lincoln NB, Palmer RL, das Nair R, Latimer NR, Hackney GL, Mandefield L, Walters SJ, Hatton RD , Cooper CL et al (2019) . Health Technology Assessment, 23(47), 1-176.
• Latimer NR, White IR, Abrams KR & Siebert U (2019) . Statistical Methods in Medical Research, 28(8), 2475-2493.
• Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT & Wong SL (2019) . Value in Health, 22(7), 772-776.
• Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N & Briggs A (2019) . PharmacoEconomics, 1-10.
• Latimer N, Abrams KR & Siebert U (2019) . BMC Medical Research Methodology, 19, 69-69.
• Bullement A, Latimer NR & Bell Gorrod H (2018) . Value in Health.
• Hernandez-Villafuerte K, Fischer A & Latimer NR (2018) . International Journal of Technology Assessment in Health Care, 34(3), 300-316.
• Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N, Charles Victor J & Hoch JS (2018) . PharmacoEconomics.
• Latimer NR, Abrams KR, Lambert PC, Morden JP & Crowther MJ (2018) . Statistical Methods in Medical Research, 27(3), 765-784.
• Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) . PharmacoEconomics.
• Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) . Medical Decision Making, 37(4), 377-390.
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2017) . Statistical Methods in Medical Research, 26(2), 724-751.
• Skaltsa K, Ivanescu C, Naidoo S, Phung D, Holmstrom S & Latimer NR (2017) . Targeted Oncology, 12(1), 111-121.
• Henshall C, Latimer NR, Sansom L & Ward RL (2016) . International Journal of Technology Assessment in Health Care, 32(3), 167-174.
• Latimer NR, Henshall C, Siebert U & Bell H (2016) . International Journal of Technology Assessment in Health Care, 32(3), 160-166.
• Thomas SA, Coates E, das Nair R, Lincoln NB, Cooper C, Palmer R, Walters SJ, Latimer NR, England TJ, Mandefield L , Chater T et al (2016) . Pilot and Feasibility Studies, 2(1).
• Hatswell AJ, Porter J, Lee D, Hertel N & Latimer NR (2016) . Value in Health.
• Latimer NR, Bell H, Abrams KR, Amonkar MM & Casey M (2016) . Cancer Medicine, 5(5), 806-815.
• Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Pandite L & Motzer RJ (2016) . Oncology, 90(3), 119-126.
• Naidoo S, Ivanescu C, Skaltsa K, Phung D, Holmstrom S & Latimer N (2015) . Value in Health, 18(3), A195-A195.
• Palmer R, Cooper C, Enderby P, Brady M, Julious S, Bowen A & Latimer N (2015) . Trials, 16(1).
• Mukherjee SC, Latimer N, Richards P, Nixon RM & Hall PS (2015) . Value in Health, 18(7), A700-A700.
• Porter J, Latimer N, Lee D & Hatswell AJ (2015) . Value in Health, 18(7), A687-A687.
• Latimer NR, Amonkar MM, Stapelkamp C & Sun P (2015) . Melanoma Research, 25(6), 528-536.
• Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C & Swann RS (2015) . The Oncologist, 20(7), 798-805.
• Latimer NR (2015) . Expert Review of Pharmacoeconomics & Outcomes Research, 15(4), 561-564.
• Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N & Hoch JS (2015) . Aphasiology, 29(7), 763-780.
• Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) . PharmacoEconomics, 32(12), 1171-1183.
• Angus C, Latimer N, Preston L, Li J & Purshouse R (2014) . Frontiers in Psychiatry.
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2014) . Med Decis Making, 34(3), 387-402.
• Latimer NR (2014) . Med Decis Making, 34(3), 279-282.
• Goyder E, Hind D, Breckon J, Dimairo M, Minton J, Everson-Hock E, Read S, Copeland R, Crank H, Horspool K , Humphreys L et al (2014) . Health Technol Assess, 18(13), 1-210.
• Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, Bermingham A, Clark TW, Latimer N, Fraser M , Perera N et al (2014) . Health Technol Assess, 18(36), 1-viii.
• Watkins C, Huang X, Latimer N, Tang Y & Wright EJ (2013) . Pharmaceutical Statistics, 12(6), 348-357.
• Latimer NR, Dixon S & Palmer R (2013) . Int J Technol Assess Health Care, 29(4), 402-409.
• Latimer N, Dixon S, Drahota AK & Severs M (2013) . Age Ageing, 42(5), 641-645.
• Abrams KR, Latimer N, Amonkar M, Stapelkamp C & Casey M (2013) . Journal of Clinical Oncology, 31(15_suppl), 9040-9040.
• Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) . Journal of Clinical Oncology, 31(15_suppl), 636-636.
• Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) . Journal of Clinical Oncology, 31(15_suppl), 9044-9044.
• Collins M & Latimer N (2013) . BMJ, 346, f1363.
• Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, Preston LR & Meier PS (2013) . Alcohol Alcohol, 48(2), 180-188.
• Whitehurst DGT & Latimer NR (2013) . Medical Acupuncture, 25(1), 2-4.
• Latimer NR (2013) . Med Decis Making, 33(6), 743-754.
• Latimer NR, Bhanu AC & Whitehurst DGT (2012) . Acupuncture in Medicine, 30(3), 182-186.
• Palmer R, Enderby P, Cooper C, Latimer N, Julious S, Paterson G, Dimairo M, Dixon S, Mortley J, Hilton R , Delaney A et al (2012) . Stroke, 43(7), 1904-1911.
• Mulhern B, Rowen D, Jacoby A, Marson T, Snape D, Hughes D, Latimer N, Baker GA & Brazier JE (2012) . Epilepsy and Behavior, 24(1), 36-43.
• Morden JP, Lambert PC, Latimer N, Abrams KR & Wailoo AJ (2011) . BMC Med Res Methodol, 11, 4.
• Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J & Conaghan PG (2011) . Pharmacoeconomics, 29(3), 225-237.
• Latimer N (2009) . Acupunct Med, 27(2), 72-75.
• Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG & National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group (2009) . BMJ, 339, b2538.
• Barham L, Lewis D & Latimer N (2007) . Sex Transm Infect, 83(6), 441-446.
• Alshreef A, Latimer N, Tappenden P & Dixon S () . Medical Decision Making.
• Latimer NR, Taylor K, Hatswell AJ, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D () . PharmacoEconomics.
• Latimer NR & Rutherford MJ () . PharmacoEconomics.
• Lally P, Kennedy F, Smith S, Beeken R, Buck C, Thomas C, Counsell N, Wyld L, Martin C, Williams S , Roberts A et al () The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate, and colorectal cancer in the UK. Cancer Medicine.
• Chang JY, Chilcott JB & Latimer N () Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments. PharmacoEconomics.
• Latimer NR, Dewdney A & Campioni M () . BMC Medical Research Methodology, 24(1).
• Swaby L, Perry DC, Walker K, Hind D, Mills A, Jayasuriya R, Totton N, Desoysa L, Chatters R, Young B , Sherratt F et al () . Bone & Joint Open, 4(11), 873-880.
• Broomfield J, Abrams KR, Freeman S, Latimer N, Rutherford MJ & Crowther MJ () . Statistics in Medicine.
• Sweeting MJ, Rutherford MJ, Jackson D, Lee S, Latimer NR, Hettle R & Lambert PC () . Medical Decision Making.
• Latimer NR, Bhadhuri A, Alshreef AO, Palmer R, Cross E, Dimairo M, Julious S, Cooper C, Enderby P, Brady MC , Bowen A et al () . Clinical Rehabilitation, 026921552097534-026921552097534.
• Goyder EC, Maheswaran R & Read S () . Journal of Public Health.
• Tai T-A, Latimer N, Benedict A, Kiss Z & Nikolaou A () Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to NICE and Impact on Decision-Making. Value in Health.
• Gray J, Sullivan T, Latimer N, Salter A, Sorich M, Ward R & Karnon J () Extrapolation of survival curves using standard parametric models and flexible parametric spline models: comparisons in large registry cohorts with advanced cancer. Medical Decision Making.
• Latimer N, Pollard D, Towse A, Henshall C, Sansom L, Ward R, Bruce A & Deakin C () . BMC Health Services Research.

Conference proceedings papers

• Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) TESTING A SURVIVAL EXTRAPOLATION ALGORITHM FOR CANCER IMMUNOTHERAPIES: PASS OR FAIL?. VALUE IN HEALTH, Vol. 26(12) (pp S13-S13)
• Franklin M, Porter A, de Vocht F, Kearns B, Latimer N, Hernandez M, Young T & Kidger J (2023) COMBINING CAUSAL INFERENCE AND WITHIN-TRIAL ECONOMIC EVALUATION METHODS TO ASSESS THE COST-EFFECTIVENESS OF A MENTAL HEALTH SERVICE USING REAL-WORLD DATA: THE QUASI-EXPERIMENTAL ADAPT STUDY. VALUE IN HEALTH, Vol. 26(12) (pp S87-S87)
• Gorrod BH, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) ADJUSTING FOR SWITCHES TO MULTIPLE TREATMENTS IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF INVERSE PROBABILITY WEIGHTING AND TWO-STAGE ESTIMATION METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S394-S394)
• Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) EVALUATING BIAS ASSOCIATED WITH INADEQUATE VARIABLE SELECTION WHEN USING INVERSE PROBABILITY OF CENSORING WEIGHTS TO ADJUST FOR TREATMENT SWITCHES IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(12) (pp S423-S424)
• Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) ACCOUNTING FOR STUDY HETEROGENEITY WHEN MODELLING THE MULTI-STATE NATURAL HISTORY OF RARE DISEASES. VALUE IN HEALTH, Vol. 26(12) (pp S421-S422)
• Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) . Value in Health, Vol. 25(12 Suppl) (pp S461-S461). Vienna, Austria, 6 November 2022 - 9 November 2022.
• Kennedy F, Miller N, Roberts A, Beeken RJ, Greenfield D, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) Promoting physical activity via a smartphone application in people living with breast, prostate or colorectal cancer: study protocol for a randomised pilot trial (APPROACH). PSYCHO-ONCOLOGY, Vol. 31 (pp 20-20)
• Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529)
• Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520)
• Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) Application of the Target Trial Framework for Estimating Comparative Effectiveness Using Real-World Data - A Systematic Review. VALUE IN HEALTH, Vol. 25(12) (pp S461-S461)
• Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616)
• Amy J-YC, Latimer NR, Gillespie D & Chilcott J (2020) PREVALENCE, CHARACTERISTICS AND KEY ISSUES OF MODELLING TREATMENT SEQUENCES IN HEALTH ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW OF NICE TECHNOLOGY APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S606-S606)
• Latimer N, White I, Tilling K & Siebert U (2020) ESTIMATING THE TRUE VALUE OF NEW ONCOLOGY TREATMENTS: IMPROVED TWO-STAGE ESTIMATION TO ADJUST FOR TREATMENT SWITCHING IN RANDOMISED TRIALS. MEDICAL DECISION MAKING, Vol. 40(1) (pp E294-E295)
• Tai TA, Latimer NR, Benedict Á, Kiss Z & Nikolaou A (2019) . Value in Health, Vol. 22 (pp S464-S464)
• Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) . Nephrology Dialysis Transplantation, Vol. 34(Supplement_1)
• Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 34
• Tai TA, Latimer NR, Benedict A, Kiss Z & Nikolaou A (2019) IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING. VALUE IN HEALTH, Vol. 22 (pp S464-S464)
• O'Brien S, Cork L, Bandeira V, Bescoby R, Foroni L, Alaily L, Osborne W, Bell-Gorrod H, Latimer N, Apperley J , Hedgley C et al (2018) . Blood, Vol. 132(Supplement 1) (pp 457-457)
• Muresan B, Mamolo CM, Cappelleri JC, Mokgokong R, Palaka A, Hills RK, Latimer N & Heeg B (2018) . Blood, Vol. 132(Supplement 1) (pp 2712-2712)
• Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
• Latimer NR (2018) . Value in Health, Vol. 21 (pp S68-S68)
• Thomas SA, Drummond A, Lincoln NB, Palmer R, dasnair R, Latimer N, Hackney G, Hatton R, Walters S, Mandefield L , Cooper C et al (2017) Behavioural activation therapy for depression after stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. INTERNATIONAL JOURNAL OF STROKE, Vol. 12 (pp 15-15)
• Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) . Value in Health, Vol. 20(9) (pp A769-A769)
• Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) . Value in Health, Vol. 20(9) (pp A718-A718)
• Latimer N & Abrams KR (2017) TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 20(5) (pp A314-A314)
• Gorrod BH, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) ADJUSTING FOR TREATMENT SWITCHING IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY. VALUE IN HEALTH, Vol. 20(9) (pp A718-A718)
• Watkins CL, Latimer N, Wang J & Wright EJ (2016) . Value in Health, Vol. 19(7) (pp A398-A398)
• Bell H, Latimer N, Amonkar M & Swann S (2015) . Value in Health, Vol. 18(7) (pp A338-A338)
• Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Bartlett-Pandite AN & Motzer R (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e15592-e15592)
• Bell H, Latimer N, Amonkar M & Casey M (2014) . Value in Health, Vol. 17(7) (pp A577-A577)
• Latimer N, Amonkar M, Stapelkamp C & Sun P (2014) . Clinical Trials
• Boucher R, Abrams KR, Crowther MJ, Lambert PC, Wailoo AJ & Latimer NR (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A610-A611)
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A325-A325)
• Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Abrams KR, Latimer N, Amonkar M, Stapelkamp C, Casey M & Grp T (2013) Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Latimer N, Lambert P, Crowther M, Abrams KR, Wailoo AJ & Morden JP (2012) . VALUE IN HEALTH, Vol. 15(7) (pp A462-A462)
• Latimer N (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A242-A242)
• Rowen D, Mulhern B, Brazier J, Jacoby A, Marson T, Latimer N, Snape D, Baker G & Hughes D (2010) Using the Liverpool Quality of Life battery to develop a health state classification system for Epilepsy. QUALITY OF LIFE RESEARCH, Vol. 19 (pp 57-57)
• Gyldmark M, Gatzemeier U, Nicolson M, Latimer N & Walzer S (2008) EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM. VALUE HEALTH, Vol. 11(6) (pp A357-A357)
• Ducournau P, Latimer N, Sabate E & Walzer S (2008) EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE. VALUE HEALTH, Vol. 11(6) (pp A471-A472)
• Latimer N & Lewis G (2008) The cost of adults with severe active rheumatoid arthritis who do not respond to treatment following treatment with one TNF inhibitor. RHEUMATOLOGY, Vol. 47 (pp II123-II124)
• Somerville M, Scott D, Hancock M, Geary U & Latimer N (2008) The impact of rituximab on resource use in a UKNHS rheumatology day care service. RHEUMATOLOGY, Vol. 47 (pp II119-II120)
• Latimer N & Lewis G (2008) What are the costs of treating severe active rheumatoid arthritis with TNF inhibitors, rituximab and abatacept?. RHEUMATOLOGY, Vol. 47 (pp II122-II123)
• Latimer NR & Lewis GJ (2005) A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK. VALUE HEALTH, Vol. 8(6) (pp A58-A58)

Reports

• Chang J-YA, Chilcott JB & Latimer NR (2024) Leveraging real-world data to assess treatment sequences in health economic evaluations: a study protocol for emulating target trials using the English Cancer Registry and US Electronic Health Records-Derived Database
• Latimer N & Pollard D (2019) Pre-read document 1: Challenges in valuing and paying for combination regimens in oncology
• Latimer NR, White IR, Abrams KR & Sieburt U (2017) Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ & Morden JP (2014) Assessing methods for dealing with treatment crossover in clinical trials: A follow-up simulation study

Scholarly editions

• Mulhern B, Rowen D, Brazier J, Jacoby A, Marson T, Snape D, Hughes D, Latimer N & Baker GA (2010) Developing a health state classification system from NEWQOL for epilepsy using classical psychometric techniques and Rasch analysis: a technical report.

Posters

• Bell H, Latimer N, Amonkar M & Casey M Adjusting for treatment crossover in a trametinib metastatic melanoma RCT: Identifying the appropriate method.

Other

• Palmer R, Cooper C, Enderby P, Brady M, Julious S, Bowen A, Latimer N, Gossage-Worrall R, Cross E & Harrison M (2018) Big CACTUS study protocol v5.0 31may17.

Preprints

• Franklin M, Porter A, De Vocht F, Kearns B, Latimer N, Alava MH, Young T & Kidger J (2023) .
• Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al () , Research Square Platform LLC.